The Intellectual Property Court of the Supreme People’s Court issued Judgment (2019) Zui Gao Fa Zhi Xing Zhong No. 127 (the judgment) on December 6 2019, maintaining the first instance decision made by the Beijing IP Court, which rescinds the Reexamination Decision No. 129924 (the decision) made by the China National Intellectual Property Administration (CNIPA). The judgment, which relates to an invention of monoclonal antibodies, could serve as a point of reference in the examination of biomedical inventions for both examiners and applicants.